MedTrace Logo

SMART Brain Health in African-Americans

NCT03861832 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2019-03-04

No results posted yet for this study

Summary

The investigators hypothesize that opioid use in African-Americans will be associated with hypodopaminergic alleles that alter the threshold for activating feelings of reward and pleasure within the dopaminergic system, and that these allelic frequencies will differ significantly from European Americans. Planned is a targeted system to study genetic risks for reward deficiency using risk gene panel to assign a genetic addiction risk score (GARS), comprehensive surveys to determine quality of life and exposure to stressors and trauma. This system will allow prediction of addiction and relapse potential and delivery of personalized treatment.

Conditions

Interventions

DIETARY_SUPPLEMENT

KB220Z

Acts to enhance dopamine

DIETARY_SUPPLEMENT

Placebo

A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical

Sponsors & Collaborators

  • Medical Home Development Group

    collaborator UNKNOWN

  • Geneus Health

    collaborator UNKNOWN

  • Howard University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-16
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03861832 on ClinicalTrials.gov